Tags

Type your tag names separated by a space and hit enter

Immunogenicity of Low-Dose Prime-Boost Vaccination of mRNA Vaccine CV07050101 in Non-Human Primates.
Viruses. 2021 08 19; 13(8)V

Abstract

Many different vaccine candidates against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the etiological agent of COVID-19, are currently approved and under development. Vaccine platforms vary from mRNA vaccines to viral-vectored vaccines, and several candidates have been shown to produce humoral and cellular responses in small animal models, non-human primates, and human volunteers. In this study, six non-human primates received a prime-boost intramuscular vaccination with 4 µg of mRNA vaccine candidate CV07050101, which encodes a pre-fusion stabilized spike (S) protein of SARS-CoV-2. Boost vaccination was performed 28 days post prime vaccination. As a control, six animals were similarly injected with PBS. Humoral and cellular immune responses were investigated at time of vaccination, and two weeks afterwards. No antibodies could be detected at two and four weeks after prime vaccination. Two weeks after boost vaccination, binding but no neutralizing antibodies were detected in four out of six non-human primates. SARS-CoV-2 S protein-specific T cell responses were detected in these four animals. In conclusion, prime-boost vaccination with 4 µg of vaccine candidate CV07050101 resulted in limited immune responses in four out of six non-human primates.

Authors+Show Affiliations

Laboratory of Virology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT 59840, USA.Laboratory of Virology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT 59840, USA.Laboratory of Virology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT 59840, USA.Laboratory of Virology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT 59840, USA.Rocky Mountain Veterinary Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT 59840, USA.Rocky Mountain Veterinary Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT 59840, USA.CureVac AG, 72076 Tuebingen, Germany.Laboratory of Virology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT 59840, USA.

Pub Type(s)

Journal Article
Research Support, N.I.H., Intramural

Language

eng

PubMed ID

34452509

Citation

van Doremalen, Neeltje, et al. "Immunogenicity of Low-Dose Prime-Boost Vaccination of mRNA Vaccine CV07050101 in Non-Human Primates." Viruses, vol. 13, no. 8, 2021.
van Doremalen N, Fischer RJ, Schulz JE, et al. Immunogenicity of Low-Dose Prime-Boost Vaccination of mRNA Vaccine CV07050101 in Non-Human Primates. Viruses. 2021;13(8).
van Doremalen, N., Fischer, R. J., Schulz, J. E., Holbrook, M. G., Smith, B. J., Lovaglio, J., Petsch, B., & Munster, V. J. (2021). Immunogenicity of Low-Dose Prime-Boost Vaccination of mRNA Vaccine CV07050101 in Non-Human Primates. Viruses, 13(8). https://doi.org/10.3390/v13081645
van Doremalen N, et al. Immunogenicity of Low-Dose Prime-Boost Vaccination of mRNA Vaccine CV07050101 in Non-Human Primates. Viruses. 2021 08 19;13(8) PubMed PMID: 34452509.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Immunogenicity of Low-Dose Prime-Boost Vaccination of mRNA Vaccine CV07050101 in Non-Human Primates. AU - van Doremalen,Neeltje, AU - Fischer,Robert J, AU - Schulz,Jonathan E, AU - Holbrook,Myndi G, AU - Smith,Brian J, AU - Lovaglio,Jamie, AU - Petsch,Benjamin, AU - Munster,Vincent J, Y1 - 2021/08/19/ PY - 2021/07/07/received PY - 2021/08/13/revised PY - 2021/08/17/accepted PY - 2021/8/28/entrez PY - 2021/8/29/pubmed PY - 2021/9/14/medline KW - COVID KW - CureVac KW - NHP KW - SARS-CoV-2 KW - vaccine JF - Viruses JO - Viruses VL - 13 IS - 8 N2 - Many different vaccine candidates against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the etiological agent of COVID-19, are currently approved and under development. Vaccine platforms vary from mRNA vaccines to viral-vectored vaccines, and several candidates have been shown to produce humoral and cellular responses in small animal models, non-human primates, and human volunteers. In this study, six non-human primates received a prime-boost intramuscular vaccination with 4 µg of mRNA vaccine candidate CV07050101, which encodes a pre-fusion stabilized spike (S) protein of SARS-CoV-2. Boost vaccination was performed 28 days post prime vaccination. As a control, six animals were similarly injected with PBS. Humoral and cellular immune responses were investigated at time of vaccination, and two weeks afterwards. No antibodies could be detected at two and four weeks after prime vaccination. Two weeks after boost vaccination, binding but no neutralizing antibodies were detected in four out of six non-human primates. SARS-CoV-2 S protein-specific T cell responses were detected in these four animals. In conclusion, prime-boost vaccination with 4 µg of vaccine candidate CV07050101 resulted in limited immune responses in four out of six non-human primates. SN - 1999-4915 UR - https://www.unboundmedicine.com/medline/citation/34452509/Immunogenicity_of_Low_Dose_Prime_Boost_Vaccination_of_mRNA_Vaccine_CV07050101_in_Non_Human_Primates_ L2 - https://www.mdpi.com/resolver?pii=v13081645 DB - PRIME DP - Unbound Medicine ER -